Collaborative Research Laboratory

Department of Electronic Health Record Department of Structural Bioscience for Taste Molecular Recognition
Alliance Laboratory for Advanced Medical Research Department of Drug Discovery for Lung Diseases

 
Translational Research Department for Skin and Brain Diseases

Department of Electronic Health Record

– Expansion of the frontier of Electronic Health Record (EHR) –
Current information science leads a new era, which provides new knowledge with massive data stream analysis. To extend the possibility of treatment and clinical study outcome, infrastructure of medical information should mediate information sources beyond the border between health and disease.
The EHR Research Unit aims to achieve personalized healthcare information infrastructure by research collaboration with multiple domain companies; information technology (IT) service consultation, medicine manufacture, laboratory testing services, and care services.
Electronic Health Record(EHR) study consists of standardization, massive data access technology, massive data analysis, medical and health care collaboration support, secondary use of medical information such as clinical study, legal validity issue, and so on.
Therefore, several research topics, which are fundamental to social installation of an EHR, are listed to each collaborative company.
Social design and installation are also promoted by collaboration with NPO, which is an alliance of EHR researchers.
Recently, nationwide EHR establishment are promoted by government in several countries.
Also, Japanese government realized that the necessity of nationwide EHR to incuvate various medical business.
In these circumstances, our lab performs research and education collabollation with international commuity openEHR, and students, such as Thailand, Philippines, Lebanon, and Grenada.



Staff:
Associate Professor: Naoto Kume
Lecturer: Shinji Kobayashi
Emeritus Professor: Hiroyuki Yoshihara

Collaboration:
GlaxoSmithKline K.K.
Life Science Institute, Inc.
NTT DATA Corporation
SRL, Inc.
Tokyo Midtown Medicine Co., Ltd.
RadianceWare Inc.

・Department of EHR:http://ehr.design.kyoto-u.ac.jp/


Department of Structural Bioscience for Taste Molecular Recognition

Under construction

Alliance Laboratory for Advanced Medical Research (Alliance Station)
-Collaboration Framework for Drug Discovery Research with Astellas-

There are still many unmet medical needs in the world including those of intractable diseases and rare diseases. Due to their complexity and rarity, mechanisms of these diseases are more difficult to be clarified, and drug discovery for these diseases requires an understanding of disease pathologies in humans. Thus, researches using blood and other clinical samples to identify molecules and cells critically associated with patients’ diseases, and those determining patient stratification are being highly demanded. In order to exploit findings of these studies and deliver innovative drugs to patients as soon as possible, efficient and in-depth research collaborations between academia and pharmaceutical company are needed in situations close to the clinical setting and diseases.
To further accelerate drug discovery research through evolution of the open innovation system of the AK Project*, where, clinical and basic research of the university and drug discovery research of the company are closely linked in a timely manner, Kyoto University and Astellas established Alliance Station (A-Station), a new open innovation scheme at Kyoto University, and the Alliance Laboratory for Advanced Medical Research as a framework for the implementation of its activities. A-Station is a new platform for collaboration between industry and academia and under this scheme, Kyoto University and Astellas will conduct joint research projects in all therapeutic areas in a prompt and flexible manner.Director:Shuh Narumiya(Professor, Graduate school of Medicine)
Industrial Partner:Astellas Pharma Inc.* AK Project: Collaborative research conducted by Kyoto University and Astellas from July 2007 to March 2017 in “Center for Innovation in Immunoregulative Technologies and Therapeutics” as a “Creation of Innovation Centers for Advanced Interdisciplinaly Resarch Areas Prgram” funded by the the Ministry of Education, Culture, Sports, Science and Technology.

Department of Drug Discovery for Lung Diseases

In the era of an aging society, lung diseases such as pulmonary fibrosis, lung cancer, COPD, bronchial asthma and pneumonia have an increasing impact on healthy life expectancy. Although more than two trillion yen is spent for lung diseases each year in Japan, the therapeutic agents for lung diseases are still limited. We think that one of the reasons is the complexity of human lung structure, consisting of various cells and matrices forming numerous tracheal branches and >300 million alveoli with elaborate network of blood vessels. However, the recent progress in human lung cell biology has made it possible to initiate this project of drug discovery for refractory lung diseases under the collaboration of academic and industrial researchers in Kyoto University.

Translational Research Department for Skin and Brain Diseases

Our aim is development of new drugs for diseases of skin and central nervous system (CNS). To realize it, basic researchers and clinical experts work together in cooperation with industrial scientists. Atopic dermatitis is one of the diseases targeted in the dermatology area, and more than 400,000 patients suffer atopic dermatitis in Japan. Although the mainstream of treatment is immunosuppressive agents such as topical corticosteroids or tacrolimus ointment, the therapeutic effects are insufficient in many cases. Therefore, development of new drugs for atopic dermatitis has been waited for. In this department, we will develop new drugs targeting itching. In the area of ​​the CNS, we will try to develop novel drugs against CNS diseases such as Alzheimer’s disease, chronic fatigue syndrome, and pain syndrome, for which we do not have any satisfactory treatment now. We believe we can develop novel therapeutic agents to control disease progression and improve symptoms by modifying neurotransmitter functions.
For compounds fully analyzed and demonstrated to be effective, we promptly conduct clinical trials. Our goal is to deliver new drugs for patients.